NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has received FDA clearance to proceed with human trials for its Investigational New Drug (IND) application for NRX-101, aimed at treating Chronic Pain. The IND application is based on pioneering research on the use of D-cycloserine, a key ingredient of NRX-101, and a recently licensed US Patent for the use of D-cycloserine in pain treatment.
October 02, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA clearance for NRx Pharmaceuticals to proceed with human trials for NRX-101 could potentially boost the company's stock in the short term as it represents a significant step forward in the drug's development process.
The FDA clearance is a significant milestone in the drug development process. It indicates that the FDA believes the drug has potential and is safe enough to be tested in humans. This news could increase investor confidence in NRx Pharmaceuticals and potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100